S&P 500
5,941.64
-0.4%
-21.96
DJI
42,685.10
-0.2%
-106.97
NASDAQ
$19,143.36
-0.4%
-$72.11
Bitcoin
106,177.00
+0.9%
+904.73
AAPL
$206.72
-1.0%
-$2.06
AMZN
$203.87
-1.1%
-$2.29
GOOG
$165.99
-1.1%
-$1.88
META
$636.61
-0.6%
-$3.82
MSFT
$456.76
-0.5%
-$2.11
NVDA
$133.97
-1.2%
-$1.60
TSLA
$351.18
+2.7%
+$9.09
Neumora Therapeutics (NASDAQ: NMRA)
$0.72
(3.8%)
$0.03
Price as of May 20, 2025, 1:58 p.m. ET
Neumora Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Neumora Therapeutics Company Info
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.
News & Analysis
Featured Article
What Companies Does SoftBank Own?
Matt Frankel | Jan 10, 2025
Featured Article
Why Shares of Neumora Therapeutics Slumped This Week
The clinical-stage biotech just had its IPO last week.
Jim Halley | Sep 21, 2023
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.